| Objective To compare and analyze clinical efficacy and safety of ganciclovir and acyclovir in treatment of varicella. Methods One hundred and ten varicella patients admitted to our hospital from June 2017 to June 2018 were equally divided into acyclovir group and ganciclovir group according to random number method, with 55 cases in each group. Clinical efficacy, the time of clinical symptoms improvement, the incidence of adverse reactions and the drug safety were compared and analyzed between 2 groups. Results After 7 days of treatment, the total effective rate in ganciclovir group was 96.36%, which was obviously higher than that in acyclovir group (78.18%), and the difference was statistically significant (P＜0.05). The time of varicella zoster virus negative transformation in the ganciclovir group was (1.58±1.01) d, which was shorter than that in the acyclovir group (2.92±1.06) d. Moreover, the time of blister scarring, the antipyretic time, the time of pain and itch relief in the ganciclovir group were significantly shorter than those in the acyclovir group (P＜0.05). The incidence of adverse reactions in the ganciclovir group was 3.64%, which was lower than that in the acyclovir group (14.55%), and the difference was statistically significant (P＜0.05). Conclusions In some case of balanced basic clinical data, ganciclovir has a greater clinical promotion value than acyclovir, due to a higher total effective rate, shorter time of blister scarring and clinical symptoms improvement, higher safety and lower incidence of adverse reaction in the treatment of varicella. |